- Home
- GSIW vs KPRX Comparison
GSIW vs KPRX Comparison
Compare GSIW & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSIW
- KPRX
- Stock Information
- Founded
- GSIW 2016
- KPRX 1998
- Country
- GSIW Hong Kong
- KPRX United States
- Employees
- GSIW N/A
- KPRX N/A
- Industry
- GSIW
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- GSIW
- KPRX Health Care
- Exchange
- GSIW Nasdaq
- KPRX Nasdaq
- Market Cap
- GSIW 8.1M
- KPRX 9.2M
- IPO Year
- GSIW 2023
- KPRX N/A
- Fundamental
- Price
- GSIW $0.18
- KPRX $2.75
- Analyst Decision
- GSIW
- KPRX Strong Buy
- Analyst Count
- GSIW 0
- KPRX 1
- Target Price
- GSIW N/A
- KPRX $10.00
- AVG Volume (30 Days)
- GSIW 13.8M
- KPRX 35.6K
- Earning Date
- GSIW 01-01-0001
- KPRX 11-07-2025
- Dividend Yield
- GSIW N/A
- KPRX N/A
- EPS Growth
- GSIW N/A
- KPRX N/A
- EPS
- GSIW N/A
- KPRX N/A
- Revenue
- GSIW $5,368,221.00
- KPRX N/A
- Revenue This Year
- GSIW N/A
- KPRX N/A
- Revenue Next Year
- GSIW N/A
- KPRX N/A
- P/E Ratio
- GSIW N/A
- KPRX N/A
- Revenue Growth
- GSIW 283.23
- KPRX N/A
- 52 Week Low
- GSIW $0.09
- KPRX $2.25
- 52 Week High
- GSIW $2.59
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- GSIW 54.81
- KPRX 55.26
- Support Level
- GSIW $0.14
- KPRX $2.67
- Resistance Level
- GSIW $0.16
- KPRX $2.89
- Average True Range (ATR)
- GSIW 0.02
- KPRX 0.11
- MACD
- GSIW 0.01
- KPRX 0.02
- Stochastic Oscillator
- GSIW 91.84
- KPRX 70.26
About GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.